Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 106635-80-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. If tafenoquine is needed by the mother, testing the mother and infant for G6PD deficiency is required before the drug is given. Because the half-life of tafenoquine averages 15 days, the manufacturer recommends that breastfeeding should not breastfeed for 3 months after the dose if the infant is G6PD deficient.
Drug Levels
Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Tafenoquine
CAS Registry Number
106635-80-7
Drug Class
- Breast Feeding
- Anti-Infective Agents
- Antiparasitic Agents
- Antimalarials
- Antiprotozoal Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Tafenoquine and G6PD: a primer for clinicians.[J Travel Med. 2019]Review Tafenoquine and G6PD: a primer for clinicians.Chu CS, Freedman DO. J Travel Med. 2019 Jun 1; 26(4).
- Review Primaquine.[Drugs and Lactation Database (...]Review Primaquine.. Drugs and Lactation Database (LactMed®). 2006
- Review Sorafenib.[Drugs and Lactation Database (...]Review Sorafenib.. Drugs and Lactation Database (LactMed®). 2006
- Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.[Am J Trop Med Hyg. 2017]Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Möhrle JJ, Rousell V, Mohamed K, Qureshi A, Narayan S, et al. Am J Trop Med Hyg. 2017 Sep; 97(3):702-711. Epub 2017 Jul 27.
- Review Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.[Cochrane Database Syst Rev. 2015]Review Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.Rajapakse S, Rodrigo C, Fernando SD. Cochrane Database Syst Rev. 2015 Apr 29; 2015(4):CD010458. Epub 2015 Apr 29.
- Tafenoquine - Drugs and Lactation Database (LactMed®)Tafenoquine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...